The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
FRI05 - Product Theater 2 | A CDK 4 & 6 Inhibitor with Overall Survival Data for Women With HR+, HER2- Metastatic Breast Cancer, Including Those Likely to Do Worse (non-CE) Presentation by Lilly Oncology
Join us to learn more about a CDK 4 & 6 inhibitor with overall survival data for women with HR+, HER2- metastatic breast cancer, including those likely to do worse.
Speaker(s):
Blanca
Ledezma,
MSN, NP,
Nurse Practitioner,
UCLA Santa Monica Hematology/Oncology
You must be logged in and own this session in order to
post comments.
